ALKS has been the topic of several other research reports. Goldman Sachs Group downgraded Alkermes from a neutral rating to a sell rating and cut their price target for the stock from $19.00 to $15.00 in a report on Thursday, July 30th. HC Wainwright reissued a hold rating and issued a $23.00 price target on shares of Alkermes in a report on Thursday, July 30th. Finally, Mizuho raised their price target on Alkermes from $16.00 to $19.00 and gave the stock a neutral rating in a report on Thursday, July 30th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and one has given a buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of $20.00.
NASDAQ:ALKS opened at $18.03 on Thursday. The company has a quick ratio of 2.59, a current ratio of 2.95 and a debt-to-equity ratio of 0.26. The business’s 50 day moving average is $17.56 and its two-hundred day moving average is $17.05. Alkermes has a 52 week low of $11.98 and a 52 week high of $21.93. The company has a market cap of $2.87 billion, a PE ratio of -22.54 and a beta of 1.32.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. M&T Bank Corp acquired a new position in shares of Alkermes during the 1st quarter valued at $11,536,000. Sowell Financial Services LLC grew its holdings in shares of Alkermes by 8,181.8% in the 1st quarter. Sowell Financial Services LLC now owns 1,822 shares of the company’s stock worth $26,000 after acquiring an additional 1,800 shares during the last quarter. Advisor Group Holdings Inc. acquired a new position in shares of Alkermes in the 1st quarter worth $41,000. Captrust Financial Advisors acquired a new position in shares of Alkermes in the 2nd quarter worth $123,000. Finally, Globeflex Capital L P grew its holdings in shares of Alkermes by 62.3% in the 1st quarter. Globeflex Capital L P now owns 6,599 shares of the company’s stock worth $95,000 after acquiring an additional 2,532 shares during the last quarter. Hedge funds and other institutional investors own 98.93% of the company’s stock.
Alkermes Company Profile
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability.
Further Reading: How is a management fee different from a performance fee?
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.